Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) VP Jeff Fairman sold 888 shares of the firm’s stock in a transaction on Thursday, May 5th. The stock was sold at an average price of $25.80, for a total value of $22,910.40. Following the completion of the sale, the vice president now directly owns 325,339 shares of the company’s stock, valued at approximately $8,393,746.20. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Jeff Fairman also recently made the following trade(s):
- On Tuesday, April 5th, Jeff Fairman sold 5,000 shares of Vaxcyte stock. The stock was sold at an average price of $25.59, for a total value of $127,950.00.
- On Friday, March 11th, Jeff Fairman sold 10,000 shares of Vaxcyte stock. The shares were sold at an average price of $25.50, for a total value of $255,000.00.
PCVX stock opened at $21.41 on Tuesday. The firm has a market cap of $1.24 billion, a PE ratio of -11.15 and a beta of 0.41. The business has a 50-day moving average price of $24.67. Vaxcyte, Inc. has a 12-month low of $15.51 and a 12-month high of $27.44.
Institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC acquired a new position in shares of Vaxcyte during the 1st quarter worth approximately $28,000. Nisa Investment Advisors LLC acquired a new position in Vaxcyte in the fourth quarter valued at approximately $29,000. Ensign Peak Advisors Inc acquired a new position in Vaxcyte in the fourth quarter valued at approximately $34,000. Manchester Capital Management LLC acquired a new position in Vaxcyte in the third quarter valued at approximately $38,000. Finally, Advisor Group Holdings Inc. acquired a new position in Vaxcyte in the fourth quarter valued at approximately $53,000. Institutional investors and hedge funds own 82.18% of the company’s stock.
Several research firms recently issued reports on PCVX. Zacks Investment Research cut Vaxcyte from a “buy” rating to a “hold” rating in a report on Wednesday, March 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 price objective on shares of Vaxcyte in a report on Thursday, February 24th.
Vaxcyte Company Profile (Get Rating)
Vaxcyte, Inc, a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis.
- Get a free copy of the StockNews.com research report on Vaxcyte (PCVX)
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
- Institutional Support For Tyson Foods Is Growing
- Time to Buy These 3 Oversold Mid-Caps
- Johnson Outdoors Falls On Bleak Outlook
- Littelfuse Stock is Hitting on All Cylinders
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.